Le Lézard
Classified in: Health, Science and technology
Subjects: NPT, PER

Conceptual Artist Tavares Strachan Joins Allen Institute As First Artist-In-Residence


SEATTLE, March 21, 2018 /PRNewswire-USNewswire/ -- The Allen Institute today announced that conceptual artist Tavares Strachan has joined the Allen Institute as the Institute's first Artist-in-Residence. As a globally-recognized artist who works on a massive scale from space to the arctic to living systems and human design, Strachan often explores the intersection of art, science, and the environment, making the unseen visible.

As Artist-in-Residence, he will have interactions with scientists across multiple fields ? from neuroscientists and cell biologists, to bioengineers and computational modelers. In addition, Tavares expects to interface with many leading technology organizations in the Seattle region.

"It's a great opportunity to interact with scientists at the cutting edge of technology in their fields. Having access to that kind of science just doesn't happen in regular life," says Strachan.

Tavares will be hosted by The Paul G. Allen Frontiers Group, a division of the Allen Institute dedicated to exploring the landscape of bioscience to identify and fund pioneers around the globe with ideas that advance knowledge and make the world better.

"Art and science both rely on design, imagination, and inspiration. Having a world-class conceptual artist like Tavares at the Institute will allow for mutual exploration of new territory. Tavares is accustomed to crossing boundaries, and has an instinct for direct lines to provocative actions that have produced works of great beauty and reflectiveness," says Tom Skalak, Ph.D., Executive Director of The Paul G. Allen Frontiers Group. 

Strachan will be on site at the Institute each month throughout 2018. As he aims to understand how the Institute addresses the complexities of bioscience, he will also share his knowledge and experience of expressing complex contextual ideas through play and exploration.

"Like scientists, I approach the world and process information through observation," says Strachan. "I am excited about the prospect of what the next year will bring and the creativity and cross pollination that will come through my interactions at this transformative science Institute."

About the Allen Institute
The Allen Institute is an independent, 501(c)(3) nonprofit research organization founded by philanthropist and visionary Paul G. Allen. The Allen Institute is dedicated to answering some of the biggest questions in bioscience and accelerating research worldwide. The Institute is a recognized leader in large-scale research with a commitment to an open science model. Its research institutes include the Allen Institute for Brain Science, launched in 2003, and the Allen Institute for Cell Science, launched in 2014. In 2016, the Allen Institute expanded its reach with the launch of The Paul G. Allen Frontiers Group, which identifies pioneers with new ideas to expand the boundaries of knowledge and make the world better. For more information, visit www.alleninstitute.org.

Media Contact:
Rob Piercy
1-206-548-8486
[email protected]

SOURCE Allen Institute


These press releases may also interest you

at 07:10
Science Corporation ("Science"), a leader in brain-computer interface ("BCI") technology and the developer of the Science Eye, has acquired the IP and related assets for the PRIMA retinal implant, developed by Pixium Vision SA ("Pixium") of France, a...

at 07:05
GlycoMimetics, Inc. , today announced that it will host a conference call and webcast to report first quarter 2024 financial results on Thursday, May 9, 2024 at 8:30 a.m. ET. To access the call by phone, please go to this registration link and you...

at 07:05
Harrow , a leading U.S. eyecare pharmaceutical company, today announced that it will release its financial results for the first quarter ended March 31, 2024, on Monday, May 13, 2024, after the market close. The Company will also post its first...

at 07:05
Mind Medicine (MindMed) Inc. , (the "Company" or "MindMed"), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study...

at 07:05
Mission Bio, a leader in single-cell multiomic solutions for precision medicine, today announced the launch of a new single-cell capability that enhances our understanding of translocations (chromosomal rearrangements) in gene-edited therapies....

at 07:05
Aldeyra Therapeutics, Inc. (Aldeyra) will host the Aldeyra 2024 Research & Development Day with investors and financial analysts in New York City to present recent pipeline developments relating to the RASP modulation platform and ADX-2191 for the...



News published on and distributed by: